AlloNK in Autoimmune Disease: Clinical Progress & Translational Insights

• Profile of AlloNK, ability to deeply deplete B-cells, and potential advantages over other modalities
• Early clinical insights from ongoing clinical trials in autoimmune disease
• Process strategies enabling consistency and potency at scale

Speakers:

Nick Veomett

Vice President - Corporate Development & AlloNK Program Lead

Artiva Biotherapeutics